Clinical Research Details
Title:
A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Addition of Bevacizumab in Three Cohorts of Patients with Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer
Purpose:
To evaluate hemorrhage toxicities resulting from early vs later addition of bevacizumab to patients receiving cisplatin/etoposide and radiotherapy followed by consolidation docetaxel/bevacizumab in patients with unresectable Stage III non small cell lung cancer
Study Number:
109205
Number of Patients:
182
Elgibility:
Patients must have histologic/cytologic confirmation of new primary Stage III non-small-cell lung cancer that cannot be resected.
Treatment:
There will be three different treatments for high-risk patients on this study and three different treatments for low-risk patients on this study. The group that you are in will depend on when you enter the study and what your doctor determines to be your risk for bleeding from your tumor. All patients will receive the same chemotherapy and radiation. The only difference between the groups will be timing of the bevacizumab treatment.
Principal Investigator:
Enrollment Phone:
(708) 327-3229